Atropine is no longer recommended for asystole. The American Heart Association removed it from the cardiac arrest algorithm in 2010, and it has stayed out of the guidelines ever since, including the most recent 2025 update. The standard treatment for asystole is high-quality CPR, epinephrine, and identifying reversible causes.
That said, the story is more nuanced than a flat “no.” Some research suggests atropine may offer a modest benefit when added to epinephrine during cardiac arrest with non-shockable rhythms. Here’s what changed, why, and what the current evidence actually shows.
Why Atropine Was Removed in 2010
Atropine works by blocking the vagus nerve’s slowing effect on the heart. When vagal tone is too high, it suppresses heart rate. Atropine counteracts that, allowing the heart to beat faster. This makes it highly effective for bradycardia, where the heart is beating but too slowly to maintain blood pressure and consciousness.
Asystole is a fundamentally different problem. The heart has no electrical activity at all. Blocking vagal input to a heart that isn’t generating any rhythm is, in most cases, like pressing the gas pedal on a car with no engine. The evidence available at the time of the 2010 guideline change was conflicting, mostly observational, and generally low quality. No randomized clinical trial had demonstrated that atropine improved survival to hospital discharge in cardiac arrest patients with asystole or pulseless electrical activity (PEA). Without convincing evidence of benefit, the AHA dropped it from the algorithm.
What the Research Has Shown Since
The picture hasn’t become dramatically clearer, but some studies have produced interesting findings. One study of out-of-hospital cardiac arrest patients with non-shockable rhythms (asystole or PEA) found that adding atropine to epinephrine was a predictor of survival to hospital admission. In the asystole subgroup specifically, the survival rate to hospital admission was 24.1% with atropine plus epinephrine compared to 20.8% with epinephrine alone. That raw difference wasn’t statistically significant on its own, but after adjusting for other variables in the analysis, atropine showed an odds ratio of 1.39 for survival to hospital admission, which was statistically significant.
However, a separate study of in-hospital cardiac arrest patients found no survival improvement from atropine in non-shockable rhythms. The 2025 AHA guidelines acknowledge both of these findings without reinstating atropine as a recommended treatment. The evidence remains mixed, and survival to hospital admission is not the same as survival to discharge with a good neurological outcome, which is the outcome that matters most.
What Is Used for Asystole Instead
The current approach to asystole centers on three priorities: uninterrupted chest compressions, early epinephrine, and finding a fixable cause.
Epinephrine is given intravenously at 1 mg every 3 to 5 minutes throughout the resuscitation. Unlike atropine, epinephrine directly stimulates the heart and constricts blood vessels, which can help restore a perfusing rhythm even when there’s no baseline electrical activity.
Equally important is working through the reversible causes of cardiac arrest, commonly taught as the “Hs and Ts.” The Hs are hypovolemia (low blood volume), hypoxia (low oxygen), hydrogen ion buildup (acidosis), abnormal potassium levels, and hypothermia. The Ts are tension pneumothorax (collapsed lung under pressure), cardiac tamponade (fluid compressing the heart), toxins, and thrombosis in either the lungs or coronary arteries. Asystole that results from one of these causes can sometimes be reversed if the underlying problem is identified and corrected quickly enough.
Where Atropine Is Still First-Line Treatment
Atropine remains the go-to drug for symptomatic bradycardia, a condition where the heart is beating but too slowly to keep organs properly supplied with blood. Signs include altered mental status, chest discomfort, dangerously low blood pressure, or other symptoms of shock. Both the AHA and the European Society of Cardiology endorse atropine as a first-line treatment in this scenario.
The key distinction is that in bradycardia, the heart’s electrical system is functioning but suppressed. Atropine can release that brake. In asystole, there’s no underlying rhythm to release. That’s the core reason it works reliably in one situation and not the other, and why it remains a critical medication in emergency medicine even though it’s been dropped from the cardiac arrest protocol.
The Bottom Line on Atropine and Asystole
If you’re studying ACLS or reviewing protocols, the answer on your exam is straightforward: atropine is not part of the asystole algorithm. It was removed in 2010 and has not been reinstated. The standard treatment is CPR, epinephrine every 3 to 5 minutes, and identifying reversible causes. Some research hints at a possible benefit from adding atropine, but the evidence isn’t strong or consistent enough to change current practice. In clinical settings, some providers may still use it at their discretion, but it is not part of the standard protocol.